GLP-1Coverage & appeals · GLP-1 / GIP receptor agonists

GLP-1 weight-loss denials: when coverage is winnable, and when it isn't

GLP-1 denials fall into two very different buckets: a plan that doesn't cover weight-loss drugs at all, and a plan that does but says the criteria weren't met. The first is rarely an appeal; the second often is. Knowing which you have is the whole game.

GLP-1 receptor agonists are denied for one of a few clear reasons, and the right response depends entirely on which one. A contractual exclusion of weight-loss drugs is a benefit-design decision that a medical-necessity appeal rarely changes. A denial for unmet BMI/comorbidity criteria or step-therapy is a documentation fight that is frequently winnable. And under Medicare, drugs used for weight loss are excluded by statute — coverage exists only for an approved non-weight-loss indication.

How GLP-1 weight-loss is covered

Commercial plans that cover anti-obesity medications typically require a BMI of 30 or higher (or 27 or higher with a weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), often documented lifestyle intervention, and sometimes a trial of a preferred agent first (step therapy). Drugs approved for type 2 diabetes (Ozempic, Mounjaro, Rybelsus) are covered on the diabetes benefit when that indication is documented, separate from any weight-loss coverage.

Why GLP-1 weight-loss claims get denied

  • The plan contractually excludes weight-loss drugs (a common employer-plan carve-out).
  • BMI or a qualifying comorbidity wasn't documented to the plan's threshold.
  • Step therapy: the plan requires a preferred drug or documented lifestyle program first.
  • Off-label use — a diabetes drug (e.g., Ozempic) prescribed for weight loss without the diabetes indication.
  • Medicare: the drug was prescribed for weight loss, which Part D cannot cover by statute.

Is a GLP-1 weight-loss denial worth appealing?

Sometimes worth appealing

Winnable when the denial is about unmet criteria you can in fact document — BMI, comorbidities, prior attempts, contraindication to the preferred agent. Rarely winnable when the plan excludes weight-loss drugs by contract, or under Medicare when the use is weight loss (a statutory exclusion, not a coverage judgment). When there is a covered medical indication — type 2 diabetes, established cardiovascular disease, or obstructive sleep apnea for the drugs approved for it — appeal on that indication, not on weight.

How to appeal a GLP-1 weight-loss denial

  1. 1

    Read the denial reason precisely

    Separate a contractual exclusion from an unmet-criteria denial. They need opposite strategies — only the second responds to a medical-necessity appeal.

  2. 2

    Document the criteria the plan names

    Attach the BMI, the qualifying comorbidities, prior weight-management attempts, and any contraindication or intolerance to the plan's preferred drug.

  3. 3

    Appeal on a covered indication where one exists

    If the patient has type 2 diabetes, established CVD, or OSA (for a drug approved for it), frame the appeal on that approved indication rather than weight loss.

  4. 4

    Escalate to external review

    If the internal appeal fails on a fully insured plan, an independent external review can overturn a medical-necessity denial — though not a clear contractual exclusion.

GLP-1 weight-loss — frequently asked

Does Medicare cover GLP-1 drugs for weight loss?
No. Medicare Part D is barred by statute from covering drugs used for weight loss. It can cover a GLP-1 prescribed for an approved indication such as type 2 diabetes or, where applicable, cardiovascular risk reduction — so the appeal must rest on that indication.
My plan excludes weight-loss drugs. Can I still appeal?
A medical-necessity appeal rarely overturns a contractual exclusion. Your realistic paths are a covered medical indication (diabetes, CVD, OSA), a formulary exception if the plan offers one, or asking the employer about adding the benefit.
What's the difference between Ozempic and Wegovy for coverage?
Same drug (semaglutide), different FDA-approved use: Ozempic is approved for type 2 diabetes, Wegovy for chronic weight management. Coverage follows the indication on the plan, not the molecule.

Related guides

Ozempic denialWegovy denialZepbound denialCO-50 · medical necessity

Sources

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →